Anatara Lifesciences Valuation
| ANR Stock | 0.01 0.0005 7.14% |
Anatara Lifesciences seems to be fairly valued based on Macroaxis valuation methodology. Our model approximates the value of Anatara Lifesciences from analyzing the firm fundamentals such as return on equity of -1.47, and Operating Margin of (2.23) % as well as examining its technical indicators and probability of bankruptcy.
Price Book 1.0225 | Enterprise Value 285.3 K | Enterprise Value Ebitda (1.02) | Price Sales 5.1107 | Enterprise Value Revenue 2.1812 |
Fairly Valued
Today
Please note that Anatara Lifesciences' price fluctuation is out of control at this time. Calculation of the real value of Anatara Lifesciences is based on 3 months time horizon. Increasing Anatara Lifesciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Anatara Lifesciences' intrinsic value may or may not be the same as its current market price of 0.01, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0065 | Real 0.00624 | Hype 0.008617 | Naive 0.009251 |
The intrinsic value of Anatara Lifesciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Anatara Lifesciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Anatara Lifesciences helps investors to forecast how Anatara stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Anatara Lifesciences more accurately as focusing exclusively on Anatara Lifesciences' fundamentals will not take into account other important factors: Anatara Lifesciences Cash |
|
Anatara Lifesciences Total Value Analysis
Anatara Lifesciences is presently projected to have takeover price of 285.27 K with market capitalization of 1.28 M, debt of 306.85 K, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Anatara Lifesciences fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
285.27 K | 1.28 M | 306.85 K |
Anatara Lifesciences Investor Information
About 40.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.02. Some equities with similar Price to Book (P/B) outperform the market in the long run. Anatara Lifesciences recorded a loss per share of 0.01. The entity had not issued any dividends in recent years. Based on the key indicators related to Anatara Lifesciences' liquidity, profitability, solvency, and operating efficiency, Anatara Lifesciences is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Anatara Lifesciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Anatara Lifesciences has an asset utilization ratio of 14.99 percent. This implies that the Company is making USD0.15 for each dollar of assets. An increasing asset utilization means that Anatara Lifesciences is more efficient with each dollar of assets it utilizes for everyday operations.Anatara Lifesciences Ownership Allocation
Anatara Lifesciences holds a total of 213.38 Million outstanding shares. Anatara Lifesciences retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Anatara Lifesciences Profitability Analysis
The company reported the revenue of 250.51 K. Net Loss for the year was (1.45 M) with loss before overhead, payroll, taxes, and interest of (1.07 M).About Anatara Lifesciences Valuation
The stock valuation mechanism determines Anatara Lifesciences' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Anatara Lifesciences based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Anatara Lifesciences. We calculate exposure to Anatara Lifesciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Anatara Lifesciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -674 K | -640.3 K |
Additional Tools for Anatara Stock Analysis
When running Anatara Lifesciences' price analysis, check to measure Anatara Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anatara Lifesciences is operating at the current time. Most of Anatara Lifesciences' value examination focuses on studying past and present price action to predict the probability of Anatara Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anatara Lifesciences' price. Additionally, you may evaluate how the addition of Anatara Lifesciences to your portfolios can decrease your overall portfolio volatility.